The H1N1 flu (swine flu) is primarily caused by the H1N1 strain of the flu (influenza) virus. It is a communicable viral illness causing upper and lower respiratory tract infections.

Swine flu H1N1 infects the cells that line nose, throat and lungs. The virus enters body when contaminated droplets are inhaled or transfer live virus from a contaminated surface to eyes, nose or mouth.

The most common symptoms of H1N1 infection include difficulty in breathing, chest pain, dizziness, nasal secretions, chills, fever, cough, sore throat, decreased appetite, and in some cases and lower respiratory tract disease.

Healthcare practitioners look for signs and symptoms of influenza, including H1N1 flu (swine flu) during the diagnosis. Laboratory tests like swab culture test, rapid flu test etc, can also be suggested for diagnosis.

There are several treatment options for swine influenza, most commonly antiviral drugs like oseltamivir zanamivir peramivir and baloxavir are used. Symptoms can be eased through lifestyle changes and home remedies like drinking plenty of water and using pain relievers.

Report Highlights

Global Insight Service’s, H1N1 (Swine Influenza) – Drug Pipeline Landscape, 2022 report provides an overview of the H1N1 (Swine Influenza) pipeline drugs. This report covers detailed insights on H1N1 (Swine Influenza) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. H1N1 (Swine Influenza) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Table of Contents

List of Tables
List of Figures

1. Introduction
1.1 H1N1 (Swine Influenza) – Pipeline Drugs, 2022-Coverage

2. Disease Overview – H1N1 (Swine Influenza)
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management

3. H1N1 (Swine Influenza) – Pipeline Drugs Development – Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2022
3.3 Products under Development by Companies, 2022

4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.3 Assessment by Route of Administration

5. Drug Profiles
5.1 Clinical Stage Drugs-Phase III
5.1.1 Baloxavir marboxil
5.1.2 mRNA-1010
5.2 Clinical Stage Drugs-Phase II
5.2.1 Adjuvanted Cell Culture Influenza Vaccine (aQIVc)
5.2.2 Adjuvanted FLU-v
5.2.3 CD388
5.2.4 DAS181
5.2.5 INNA-051
5.2.6 SAB-176
5.2.7 Seasonal Flu Vaccine
5.2.8 VIS410
5.3 Clinical Stage Drugs-Phase I
5.3.1 CODA-VAX H1N1
5.3.2 FLU SV Mrna
5.3.3 Influenza A Drug
5.3.4 Quadrivalent Influenza Vaccine
5.3.5 Trivalent influenza vaccine
5.3.6 UniFlu
5.4 Early Stage Drugs-Preclinical
5.4.1 AV5124
5.4.2 BWV-101
5.4.3 BWV-102
5.4.4 CBS1116
5.4.5 Drug for H1N1
5.4.6 EC-QIV
5.4.7 Flucide
5.4.8 H1N1 Flu Vaccine
5.4.9 Influenza A/B
5.4.10 Influenza Vaccine
5.4.11 Neuraminidase
5.4.12 “R327
5.4.13 Nasal”
5.4.14 Tetravalent flu VLP vaccine
5.4.15 Vaccine
5.4.16 VMTX-001
5.5 Early Stage Drugs-Discovery
5.5.1 UMIN-101

6. Key Regulatory Designations

7. Key Deals

8. Key Upcoming Milestones

9. Key Companies Involved
9.1 Abzyme Therapeutics LLC
9.2 Ansun Biopharma Inc
9.3 Blue Water Vaccines Inc
9.4 BunyaVax BV
9.5 Chicago Biosolutions Inc
9.6 Cidara Therapeutics Inc
9.7 Cocrystal Pharma Inc
9.8 Codagenix, Inc
9.9 Collaborations Pharmaceuticals Inc
9.10 CSL Ltd
9.11 Curevac NV
9.12 Dnarx LLC
9.13 Emergent BioSolutions Inc
9.14 Ena Respiratory Pty Ltd
9.15 EpiVax Inc
9.16 Genentech USA Inc
9.17 Imutex Ltd
9.18 Jiangsu Ab&b Biotechnology Co Ltd
9.19 Medicago Inc
9.20 Moderna Inc
9.21 NanoViricides Inc
9.22 Recce Pharmaceuticals Ltd
9.23 SAb Biotherapeutics, Inc
9.24 Sciogen Inc
9.25 TechnoVax Inc
9.26 UMN Pharma Inc
9.27 Viramatix Sdn Bhd
9.28 Viriom Inc
9.29 Visterra, Inc.
9.30 Zosano Pharma Corp

10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs

11. Appendix

List of Tables

Table 1. 2 Number of Products under Development by Companies
Table 1. 3 Products under Development by Companies
Table 1. 4 Products by Targets
Table 1. 5 Products by Mechanism of Action
Table 1. 6 Products by Molecule Type
Table 1. 7 Products by Route of Administration
Table 2.1 Clinical Trial Details – Baloxavir marboxil/Genentech USA Inc
Table 2.2 Clinical Trial Details – CD388/Cidara Therapeutics Inc
Table 2.3 Clinical Trial Details – mRNA-1010/Moderna Inc
Table 2.4 Clinical Trial Details – Adjuvanted Cell Culture Influenza Vaccine (aQIVc)/CSL Ltd
Table 2.5 Clinical Trial Details – Adjuvanted FLU-v/Imutex Ltd
Table 2.6 Clinical Trial Details – DAS181/Ansun Biopharma Inc
Table 2.7 Clinical Trial Details – INNA-051/Ena Respiratory Pty Ltd
Table 2.8 Clinical Trial Details – SAB-176/SAb Biotherapeutics, Inc
Table 2.9 Clinical Trial Details – Seasonal Flu Vaccine/Medicago Inc
Table 2.10 Clinical Trial Details – VIS410 /Visterra, Inc.
Table 2.11 Clinical Trial Details – CODA-VAX H1N1/Codagenix, Inc
Table 2.12 Clinical Trial Details – FLU SV Mrna/Curevac NV
Table 2.13 Clinical Trial Details – Influenza A/Cocrystal Pharma Inc
Table 2.14 Clinical Trial Details – Quadrivalent Influenza Vaccine/Jiangsu Ab&b Biotechnology Co Ltd
Table 2.15 Clinical Trial Details – Trivalent influenza vaccine/Zosano Pharma Corp
Table 2.16 Clinical Trial Details – UniFlu/Emergent BioSolutions Inc
Table 3. 1 Regulatory Designations
Table 4. 1 Inactive Drugs
Table 4. 2 Discontinued Drugs

List of Figures

Figure 1. 1 Number of Products under Development for H1N1 (Swine Influenza), 2022
Figure 1. 2 Products by Top 5 Targets and Stage of Development for H1N1 (Swine Influenza), 2022
Figure 1. 3 Products by Top 5 Mechanism of Action and Stage of Development for H1N1 (Swine Influenza), 2022
Figure 1. 4 Products by Top 5 Molecule Type and Stage of Development for H1N1 (Swine Influenza), 2022
Figure 1. 5 Products by Top 5 Route of Administration and Stage of Development for H1N1 (Swine Influenza), 2022

Report Segmentation
  • Assessment by Stage of Development
  • Assessment by Companies
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Order this Report

Have questions about the scope of the report ?

Have specific requirements ?

Budget Constraints ?

Related Reports

Diabetic neuropathy is a type of nerve damage…
Leukemia is a malignant disease of the blood…
Diabetic Gastroparesis is a serious complication of diabetes…